Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sea Run Holdings
Freeport, Maine, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Sea Run Holdings developed proprietary therapeutics and reagents derived from salmon blood, primarily plasma proteins such as fibrinogen and thrombin, demonstrating promising pre-clinical results for applications in hemostasis, wound healing, and pain relief. No clinical stage products were reported prior to acquisition. The intellectual property and ongoing research were acquired by Salmonics in 2021[1][2][3].
- Therapeutic areas
- HematologyNeurologyOtherDermatology
- Modalities
- ProteinBiologic
- Industry
- Biotech
02
Partnerships
Cooke AquacultureUniversity of PennsylvaniaUniversity of LouisvilleUniversity of California
Beyond the preview
Go deeper on Sea Run Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sea Run Holdings.